BAYN News & Analysis
2 articles
Market Mood
Pfizer (PFE) and Moderna patent case against Bayer dismissed
Pfizer (PFE), BioNTech, and Moderna have lost their attempt to dismiss a patent infringement case brought by Bayer. The court's decision allows Bayer to pursue its claim related to the technology used in mRNA vaccines. This ruling may have implications for the patent landscape in the biopharmaceutical industry, potentially affecting how companies protect their innovations. The outcome could influence future litigation involving vaccine patents, which is valuable for investors in this sector.
Read More: Pfizer (PFE) and Moderna patent case against Bayer dismissed
Bayer (BAYN) Launches Ruveon for Roundup After Legal Victory
Bayer (BAYN) has established a new business named Ruveon to manage its Roundup herbicides in the US following a legal victory regarding lawsuits over cancer claims. This new organization will focus on addressing ongoing product liability challenges, aiming to streamline operations and bolster its market position. The legal win allows Bayer to proceed further without the immediate repercussion of pending lawsuits. The formation of Ruveon signifies Bayer's strategic move to stabilize its reputation and address financial implications related to Roundup.
Read More: Bayer (BAYN) Launches Ruveon for Roundup After Legal Victory